Systemic sclerosis (SSc) is an autoimmune disease which is associated with the development of organ fibrosis and vasculopathy (1) . Patients with severe, early diffuse cutaneous SSc and significant internal organ involvement have a mortality rate of 50% at five years (2) . There are many aspects of SSc that support the hypothesis that it is an autoimmune disease and might respond to immunosuppressive therapy (3) (4) . To date, the immunomodulatory effect of thymoglobulin is not fully understood but includes increased T-cell clearance from blood, modulation of T-cell activation, elimination of cytotoxic T-cell, and increased T regulatory cells. In a pilot study, thymoglobulin was studied as single agent therapy (7). Matteson et al (8) treated 10 patients with ATGAM alone, at total dose of 10 mg/kg on 5 consecutive days; two patients having improvement.
Our center initiated trials in high dose autologous transplantation immunosuppressive therapy (ASCT) as treatment for SSc (9) . There have been durable responses seen. However, some patients had too many comorbidities or the disease had progressed to the point that they were no longer reasonable candidates for ASCT. We Two patients had initial responses for nearly one to 3 years but eventually died of cardiac events associated with life-threatening underlying pre-existing SSc-cardiac involvement; both had a history of previous episodes of arrthymias. One patient remains in remission at 69 months, having required no additional therapy.
Although this data is as yet purely anecdotal, this treatment combination appears encouraging and may signal greater response than monotherapy. This combination of cyclophosphamide and thymoglobulin, though, cannot be considered curative, but it did give some durable responses after one course. Caution should be used in giving this therapy to very ill individuals as there was one death associated with thymoglobulin.
Given the marginal clinical reserve of these patients, there is little ability to compensate in life-threatening situations. This combination may offer an alternative regimen for high-risk SSc patients with progressive disease, especially those who are not candidates for ASCT.
